Walewski, J. Et Al. 2016. SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY. 10th International Symposium on Hodgkin Lymphoma , (Cologne, Germany), 56.

Walewski, J., Hellmann, A., Siritanaratkul, N., Ozsan, G. H., Ozcan, M., Chuncharunee, S., ... Goh, A. S.(2016). SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY . 10th International Symposium on Hodgkin Lymphoma (pp.56). Cologne, Germany

Walewski, J. Et Al. "SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY," 10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 2016

Walewski, J. Et Al. "SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY." 10th International Symposium on Hodgkin Lymphoma , Cologne, Germany, pp.56, 2016

Walewski, J. Et Al. (2016) . "SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY." 10th International Symposium on Hodgkin Lymphoma , Cologne, Germany, p.56.

@conferencepaper{conferencepaper, author={J. Walewski Et Al. }, title={SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION OR MULTIAGENT CHEMOTHERAPY}, congress name={10th International Symposium on Hodgkin Lymphoma}, city={Cologne}, country={Germany}, year={2016}, pages={56} }